Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7841565> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Q7841565 subject Q5016550.
- Q7841565 subject Q7211373.
- Q7841565 abstract "A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody. In addition, its intact Fc-part can bind to an Fc receptor on accessory cells like conventional monospecific antibodies. The net effect is that this type of drug links T cells (via CD3) and monocytes/macrophages, natural killer cells, dendritic cells or other Fc receptor expressing cells to the tumor cells, leading to their destruction.At an equivalent dose a trifunctional antibody is more potent (more than 1,000-fold) in eliminating tumor cells than conventional antibodies. These drugs evoke the removal of tumor cells by means of (i) antibody-dependent cell-mediated cytoxicity, a process also described for conventional antibodies and more importantly by (ii) polyclonal cytotoxic T cell responses with emphasis on CD8 T cells. These trifunctional antibodies also elicit individual anti-tumor immune responses in cancer patients treated with e.g. catumaxomab; i.e. autologous antibodies as well as CD4 and CD8 T cells directed against the tumor were detected. Furthermore, putative cancer stem cells from malignant ascites fluid were eliminated due to catumaxomab treatment.Examples include catumaxomab (EpCAM / CD3), ertumaxomab (HER2/neu / CD3), FBTA05 (CD20 / CD3, proposed trade name Lymphomun) and TRBS07 (GD2 / CD3, proposed trade name Ektomab), drugs against various types of cancer.".
- Q7841565 thumbnail Catumaxomab_mechanism.svg?width=300.
- Q7841565 wikiPageWikiLink Q1047791.
- Q7841565 wikiPageWikiLink Q107244.
- Q7841565 wikiPageWikiLink Q14877486.
- Q7841565 wikiPageWikiLink Q14906101.
- Q7841565 wikiPageWikiLink Q1638475.
- Q7841565 wikiPageWikiLink Q170050.
- Q7841565 wikiPageWikiLink Q18028744.
- Q7841565 wikiPageWikiLink Q184204.
- Q7841565 wikiPageWikiLink Q186889.
- Q7841565 wikiPageWikiLink Q193529.
- Q7841565 wikiPageWikiLink Q193889.
- Q7841565 wikiPageWikiLink Q212354.
- Q7841565 wikiPageWikiLink Q2459684.
- Q7841565 wikiPageWikiLink Q332181.
- Q7841565 wikiPageWikiLink Q3732639.
- Q7841565 wikiPageWikiLink Q376266.
- Q7841565 wikiPageWikiLink Q3776943.
- Q7841565 wikiPageWikiLink Q408155.
- Q7841565 wikiPageWikiLink Q417823.
- Q7841565 wikiPageWikiLink Q419458.
- Q7841565 wikiPageWikiLink Q422248.
- Q7841565 wikiPageWikiLink Q425941.
- Q7841565 wikiPageWikiLink Q426141.
- Q7841565 wikiPageWikiLink Q4864602.
- Q7841565 wikiPageWikiLink Q5016550.
- Q7841565 wikiPageWikiLink Q506253.
- Q7841565 wikiPageWikiLink Q576711.
- Q7841565 wikiPageWikiLink Q7211373.
- Q7841565 wikiPageWikiLink Q855177.
- Q7841565 wikiPageWikiLink Q949267.
- Q7841565 wikiPageWikiLink Q978273.
- Q7841565 comment "A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody. In addition, its intact Fc-part can bind to an Fc receptor on accessory cells like conventional monospecific antibodies.".
- Q7841565 label "Trifunctional antibody".
- Q7841565 depiction Catumaxomab_mechanism.svg.